Adenosine (ADO) is a potent bronchoconstrictor in allergic patients and has been shown to increase the release of histamine from human lung tissues. Antagonists of ADO A, and Azn receptors are not effective in attenuating these effects. Therefore, involvement of ADO A3 receptors in the bronchoconstrictor and/or inflammatory effects have to be considered. Eosinophils also play a pivotal role in allergic diseases such as asthma, thus it is natural to consider a link between the A3 receptor and eosinophils. Human peripheral blood eosinophils express the ADO A3 receptor as indicated by detection of the transcript for A3 receptors in polymerase chain reaction-amplified cDNA derived from the cells. A3 receptors on eosinophil membranes were characterized using the AP receptor agonist radioligand '251-labeled AB-MECA, OSINOPHILS ARE thought to be closely associated E with many allergic diseases such as allergic rhinitis, bronchial asthma, or atopic dermatitis.'.' Under such circumstances, eosinophils infiltrate the tissues and release mediators that are responsible for tissue damage and inflammat i~n .~ Among the allergic diseases, asthma in particular is known to be connected with accumulation of these cells. The severity of asthma correlates with levels of circulating and bone marrow eosinophils, and the clinical evaluation of asthma usually requires a determination of eosinophil c o~n t .~.~ The histopathology of asthma shows major eosinophilic infiltration in the epithelium and lamina propria of bronchial mucosa and an associated deposition of eosinophil granule cationic p r~t e i n .~.~ Eosinophil granule proteins such as major basic protein (MBP) are able to stimulate the release of histamine, which provokes bronchoconstriction, from mast cells or basophils." Therefore, knowledge of the factors that regulate the function of eosinophils in tissues is important for the understanding of allergic diseases including asthma.
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The role of adenosine (ADO) in asthma has been explored. In asthmatics, inhalation of adenosine causes bronchoconstriction." ADO has been shown to increase the release of histamine from human lung fragments." This effect is not a direct action of ADO on smooth muscles, but rather occurs in the bronchi through the release of histamine or leukotriene from basophils and mast cells.I3 This constriction is blocked by a combination of histamine and leukotriene antag0ni~ts.l~ In asthmatics, mean ADO concentrations measured in bronchoalveolar lavage fluid are significantly elevated relative to normal patients.14 The mechanism of this ADO-induced constriction has been thought to be a response of mast cells to ADO.I3 As mentioned above, eosinophils stimulate mast cells and are able to excrete strong bronchoconstrictors such as leukotriene C, (LTC,) and platelet-activating factor (PAF) to stimulate directly smooth muscle in b r~n c h i . '~. '~ Thus, there exists a strong likelihood that eosinophils respond to ADO and other ADO receptor specific agents.
Based on biochemical and pharmacological criteria, two subtypes of ADO receptors, AI and A2, have been differentiated. However, the potency of xanthines as antagonists of ADO A, and AzA receptors are not predictive of effects in blocking bronchoconstriction." Therefore, the involvement of another member of the ADO receptor family has to be considered. Recently, a third subtype of ADO receptor, the A3 receptor, was cloned from rat brain and rat testes cDNA Its activation stimulates phosphatidyl inositol metabolism in antigen-exposed mast cells and inhibits adenylyl cyclase in transfected Chinese hamster ovary (CHO) cells." A preliminary report by Bai et alzO suggests that A3 receptors in the human lung may be associated with eosinophils rather than mast cells. We hypothesized that human peripheral blood eosinophils might express A3 receptors and, if present, that these receptors could have a role in cell function. As with mast cells, A3 receptor activation may hypothetically stimulate eosinophils, followed by phagocytosis, degranulation, production of cytokines, adhesion to endothelial surfaces, transmigration to tissues, and so forth. In the present study, we demonstrate that ADO A3 receptors are expressed on human eosinophils in relatively high density. Moreover, we found that the selective A3 receptor agoagonist , 2 -chloro -N6-( 3 -iodobenzyl )-adenosine -5 -Nmethyluronamide (Cl-IB-MECA), induces Ca" release from intracellular Caz+ pools followed by Ca2+ influx. macia, Uppsala, Sweden) density gradient centrifugation and negative selection with anti-CDI6 monoclonal antibody (MoAb) and immunomagnetic beads coated with goat antimouse IgG (Dynabeads M450; Dynal AS, Oslo, Norway) as previously described.*' The punty of eosinophils based on light microscopic examination of cytocentrifugation preparations stained by Diff-Quik (American Scientific Products, McGraw Park, IL) was >99%.
The eosinophils used in this assay were carefully isolated with particular attention given to purity. The purity based on light microscopic examination was 100%. based on random counting of 500 cells. Total RNA was prepared by the single-step method** with slight modifications (RNA STAT-60; TEL-TEST "B", INC. Friendswood, TX). One microgram of total RNA was incubated at room temperature for 15 minutes with 1 U of RNase-free DNase I (Boehringer Mannheim, Indianapolis, IN), and the first strand cDNA was synthesized with 0.5 pg of oligo (dT)12.18 primer and 200 U of the cloned M-MLV reverse transcriptase (SUPERSCRIPT I1 preamplification system; Life Technologies, Gaithersburg, MD).
The human A, ADO receptor sequence was amplified with 5' primer sequence (ACCCCCATGT'ITGGCTG) and 3' primer sequence (GCACAAGCTGTGGTACCTCA) giving a 361 bp prodUCt.23.24 The PCR was carried out in 50 p L using the following conditions: the initial denaturing step at 95°C for 2 minutes, followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, except the last elongation at 72°C for 10 minutes. Subsequently, 10 pL of PCR products were run on the 4% NuSieve 3:1 agarose gel (FMC BioProducts, Rockland, ME) and examined by ethidium bromide staining.
Binding studies using the high affinity ADO A, receptor radioligand Binding assays were performed in the lysis buffer in glass tubes with each tube containing 100 pL of the membrane suspension, 50 pL of ["'IIAB-MECA at an optional concentration and 50 pL of ADO deaminase to provide a final concentration of 3 UlmL, in the pH 7.4 lysis buffer. Membranes prepared from HEK-293 cells stably expressing the human A, receptor were obtained from Receptor Biology, Inc (Baltimore, MD). Incubations were carried out in duplicate for 1 hour at 37°C. in the presence of 1 pmoVL xanthine amine congener (XAC), added to block radioligand binding to AI receptors. The incubation was terminated by rapid filtration over Whatman GF/B filters, using a Brandell cell harvester (Gaithersburg, MD). 
RESULTS
Amplification of a A, receptor-specific sequence was performed from reverse-transcribed mRNA obtained from eosinophils. The agarose-gel electrophoresis revealed the single band of the expected 361-bp PCR product, indicating the existence of ADO A, receptor on eosinophils (Fig 1) .
The level of expression of the ADO A, receptor in human eosinophils was also determined using the high affinity radioligand ['2SI]AB-MECA2s in satuExpression of AADO receptors on eosinophils.
Radioligand binding.
For personal use only. on December 24, 2017. by guest www.bloodjournal.org From ration binding experiments (Fig 2) (Fig 3) The level of A3 receptor binding was much higher than levels of A, and AZA receptors present in the same membranes. Binding assays at A, and A2A receptors using single concentrations of radioligand were performed as described. The highly selective A3 receptor agonist, Cl-IB-MECA (10 and 30 p m o n ) , produced increases in concentrations of intracellular free Ca" ([Ca"],) (Fig 4) . It produced a rapid rise followed by a sustained increase in [Ca"],. Among the donors selected, those with more significant eosinophilia had a more pronounced [Ca2'], response, consistent with minimally activated (primed) eosinophils compared with normals. In separate experiments these patients showed increased expression of activation markers, including CD69 and CD25, on their peripheral blood eosinophils compared with normal donors ( S . Mawhorter, personal communication, March 1996). Chelation of extracellular CaZ+ with EGTA (0.5 mmoVL) did not abolish the initial rise in [Caz'],. Thus, the first rapid increase in [Ca2'], was due to Ca2+ release from intracellular CaZ+ pools, while the second phase appeared to result from an influx of extracellular Ca2' (Fig 5) . Although NECA (10 pmol/L) induced an increase in intracellular CaZ+ levels, the intensity of the elevation of [Ca"], was clearly lower than
Cytosolic ea2+ concentration.
For personal use only. on December 24, 2017. by guest www.bloodjournal.org From in eosinophils are very similar in intensity and pharmacology to those observed in HL-60 cells, for which we have also proposed a functional A3 receptor."
The role of the ADO A3 receptor on the eosinophils is unclear at present. However, when the eosinophils were exposed to a relatively high concentration of an A3 agonist, synthesized in our lab~ratory?~ that is =2,000-foId selective in binding assays at rat adenosine receptors, an increase in [Ca2'Ii was observed. Upon chelation of extracellular Ca", the initial rapid rise in [Ca"], produced by CI-IB-MECA was still present, and the later prolonged elevation was absent. These results are consistent with the presence of phospholipase C-coupled ADO A3 receptors on eosinophils. In a previous study of the effects of A3 receptor agonists on HL-60 (human promyelocytic leukemia) cells, very similar effects on [CaZfli were seen." The calcium ionophore A23 187 stimulates these cells to induce the release of granule substances and intact granules by a cytolytic mechanism.?" Some substances are known to stimulate eosinophil function, associated with mobilization of Ca2+ from intracellular stores and secretion of granule substances. Prostaglandin D23' and one of the most potent chemoattractants for eosinophils, are potent stimuli for calcium mobilization. Secretion and other functions induced by these substances appear to depend on both the release of Ca" from intracellular stores and on G Therefore, it is thought that ADO stimulates these cells via the activation of A3 receptors. resulting in the release of Ca" from intracellular stores. It is well-documented that in certain types of cells elevation of the intracellular Ca2' level induced by various agents can play a crucial role in triggering apoptosis. Also in thymocytes, an antibody against the CD3-T cell receptor complex,14 ATP'5 and were reported to induce apoptosis by Ca"-mediated mechanisms, and their effects are mimicked by treatment of the thymocytes with a calcium ionophore. In addition to thymocytes, ADO that of CI-IB-MECA (Fig 3) . NECA is not a selective agonist, although it has a relatively high affinity for the A, receptor. At concentrations of 30 @mom, CPA and CGS 21680, which would be expected to fully activate any AI or AZA receptors that may be present, had no effect on intracellular Ca2' levels in eosinophils (data not shown).
DISCUSSION
These results attest to the existence of ADO A3 receptors on eosinophils. Several methods were used to support this conclusion: (1) Saturable and high-affinity binding of For personal use only. on December 24, 2017. by guest www.bloodjournal.org From physiological functions of ADO A3 receptor are known.** We proved that A3 receptors are present on eosinophils, and our data are consistent with the possibility that the A3 receptors on the cells are involved in the etiology of various allergic diseases although the possibility that other adenosine receptors or other cells may be involved in these diseases has not been ruled out.
New selective A3 receptor antagonists are currently under development in our laboratory.26 It will be of great interest to determine if a potent antagonist would prevent the elevation of intracellular calcium concentration evoked by an A3 receptor agonist and the activation or apoptosis of the cells. It will be necessary to follow this study with an investigation on how A3 receptor activation affects eosinophil function. A3 receptor antagonists may prove to inhibit infiltration or transmigration of eosinophils to tissues including airway lumen and thus be useful therapeutically in allergic diseases.39
